HomeTagsCytoDyn

CytoDyn

Leronlimab (350 mg) Weekly Use for 14 Weeks in Open Label Arm of NASH Trial Produces Fibrosis Reduction as High as 93 msec Amongst...

CytoDyn Inc., a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, reported data from its trial treating...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics